Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)
Clinical trial NCT04241185 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04241185
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-05-19
- Primary completion
- 2027-01-31
- Enrollment
- 520
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.